Galvus belongs to a group of medicines called “oral antidiabetics”. Galvus is used to treat patients with type 2 diabetes. It is used when diabetes cannot be controlled by diet and exercise alone. It helps to control the level of sugar in the blood. This key development provides the healthcare practitioner with an alternative choice of a high quality product in managing type 2 diabetes. Diabetes is one of the world’s greatest healthcare challenges, affecting 366 million people globally and killing one person every seven seconds. The obesity epidemic and an aging world population are contributing to the escalating incidence of type 2 diabetes and by 2030 it is projected that more than half a billion people will be diagnosed with the disease. Type 2 diabetes accounts for 90 percent of all cases of the disease.